一种与棕化相关的新型分子签名,用于预测和治疗阿尔茨海默病的向
Xiuling Miao1,2, Kaiyu Luo1,2, Yinglei Li2
1Medical School of Chinese People's Liberation Army, 28 Fuxing Road, Beijing, 100853, China.
Molecular neurobiology
|December 9, 2025
概括
这项研究确定了65个与阿尔茨海默病相关的棕化相关基因,突出了七个关键基因参与突触功能. 这些发现为阿尔茨海默病 (AD) 提供了潜在的新治疗点.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 生物信息学是一种生物信息学.
背景情况:
- 阿尔茨海默病 (AD) 的特点是粉样β斑块和tau病理.
- 棕化在AD病变发生过程中的作用尚不清楚.
- 确定特定的基因和涉及的途径对于开发新疗法至关重要.
研究的目的:
- 为了研究棕细胞代谢在阿尔茨海默病中的作用.
- 确定与AD相关的关键棕化相关基因.
- 开发一种诊断模型并探索阿尔茨海默病的治疗点.
主要方法:
- 来自GEO数据库的七个转录组数据集的分析.
- 不同表达分析,基因组丰富分析 (GSEA) 和通路丰富.
- 使用蛋白质-蛋白质相互作用网络和机器学习算法 (LASSO,SVM-RFE,随机森林) 优先考虑关键基因.
主要成果:
- 确定了65个与阿尔茨海默病相关的棕化相关基因 (AD-PRG).
- 开发了一个使用七个关键AD-PRG具有高预测性能 (AUC0.834-0.907) 的诊断模型.
- 发现了与突触功能的关联,并确定了潜在的治疗点,包括miRNA和转录因子.
结论:
- 棕化在阿尔茨海默病中的突触功能障碍中起着重要作用.
- 像VAMP2和SYT1这样的关键基因与囊泡循环和神经递质释放有关.
- 已识别的基因和途径为新型阿尔茨海默病治疗提供了有希望的目标.
更多相关视频
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.6K
16:33Detection of Protein Palmitoylation in Cultured Hippocampal Neurons by Immunoprecipitation and Acyl-Biotin Exchange ABE
Published on: February 18, 2013
37.3K
相关概念视频
Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Alzheimer's Disease: Treatment
736
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
736
